

ASX ANNOUNCEMENT

5 March 2015

Cynata Presenting at 8th Annual ASX Spotlight New York 2015

Investment Conference Highlighting Opportunities Listed on the Australian Stock Exchange

Melbourne, Australia & New York, NY: 5 March 2015: Stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today CEO and Managing Director, Dr Ross Macdonald, will be presenting a Company overview and holding one-on-one meetings with institutional investors at the 8th Annual ASX Spotlight conference on Thursday, March 5, 2015 at Le Parker Meridien, New York, NY.

Dr MacDonald stated, "Cynata is pleased to have been invited to present at the ASX Spotlight New York. We look forward to sharing the forum with some of Australia's leading healthcare and technology companies. I am excited to tell the Company's story to the New York investment community."

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a consistent, reliable source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

CONTACTS:

Dr. Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr. Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, + 1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleens@pcgadvisory.com

W: www.cynata.com ABN - 98 104 037 372